Episode 172 - February 6, 2026

What It Covers

Biotech Hangout Episode 172 examines the robust IPO market with four deals pricing in one week including ICON's $400M raise, Medicare drug price negotiations impacting innovation, obesity market dynamics following Novo Nordisk's weak guidance versus Eli Lilly's $80-83B forecast, and FDA intervention against compounding pharmacies mass-marketing copycat GLP-1 drugs.

Key Questions Answered

• •IPO Market Momentum: Six biotechs completed IPOs in the first six weeks of 2026, including ICON Therapeutics raising $400M and Veridermics raising $300M, signaling a potentially robust year that could reach 20-25 total deals. Early-cycle IPOs feature higher quality companies with late-stage assets and mature platforms priced competitively against public comparables, attracting strong investor demand and establishing healthy market conditions for continued activity throughout the year.
• •Compounding Pharmacy Crackdown: FDA Commissioner Marty Makary announced swift action against HIMS and HERS for marketing compounded semaglutide at $49-99 monthly, violating compounding pharmacy regulations designed for filling unmet medical niches rather than mass-marketing copycat drugs. This represents critical IP protection for innovators, as compounding pharmacies should adjust existing drug formulations for individual patient needs, not commercialize unauthorized versions of patented therapies at scale.
• •Obesity Market Competition: Eli Lilly reported over $19B quarterly revenue beating $18B consensus with $80-83B annual guidance versus $78B expectations, while Novo Nordisk guides for 5-13% year-over-year revenue decline. Pfizer's danuglipron data shows comparable weight loss to Amgen's maritide with similar tolerability profiles, validating that monthly and potentially quarterly dosing regimens can achieve competitive efficacy once patients complete initial weekly dose escalation phases.
• •TSLP Therapeutic Landscape: Amgen and AstraZeneca's Tezspire reaches $2B run rate in year three for asthma treatment, matching DUPIXENT in new patient starts. Upstream Bio targets the TSLP receptor for potential 12-24 week dosing intervals with phase two data imminent, while Generate Bio advances directly from phase one to two phase three trials with every-six-month dosing. Physician surveys confirm strong preference for extended dosing intervals.
• •Rare Pediatric Disease Voucher Program: Congress reauthorized the rare pediatric disease priority review voucher program after stalling in spending negotiations, with Jazz Pharmaceuticals recently purchasing a PRV for $200M establishing new pricing benchmarks above the historical $100-150M range. PRV pricing fluctuates based on supply-demand dynamics, with potential increases if competitive therapeutic areas like obesity create bidding wars for accelerated review timelines among major pharmaceutical companies.